Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.–Induces responses in both crizotinib-naïve and crizotinib-resistant ALK+ NSCLC patients– -X-396 demonstrates activity in central nervous system metastases- WEST PALM BEACH, Fla.–(BUSINESS WIRE)–October 31, 2014– Xcovery, a developer of next-generation targeted therapeutics for cancer, presented results at the 2014 Multidisciplinary Symposium in Thoracic Oncology from a Phase 1/2 study of X-396, a potent small molecule anaplastic lymphoma kinase (ALK) inhibitor.
Xcovery Presents Phase 1 Results Of X-396 In Alk Positive Nsclc At The 2014 Multidisciplinary Symposium In Thoracic Oncology
Business Wire, VentureBeat
Thu, 10/30/2014 - 9:01pm
Topics: alk nsclc west palm beach fla (business wire)–october multidisciplinary symposium american society clinical oncology asco june while leora horn md msc associate professor medicine clinical director thoracic oncology program vanderbilt-ingram cancer center nashville tenn these executive vice president chief scientific officer alk-positive about xcoveryxcovery sheridan g snyder xcovery s photos/multimedia gallery xcoverymedia lavoie health sciencedavid connolly development cheryl calhoun presidentccalhoun@biocatalystintl nsclc alk xcovery thoracic oncology phase x-396 chris liang ph.d contact results patients crizotinib data patient mg lung cell activity prior response disease ceritinib non-small small presented nervous resistance well-tolerated system molecule crizotinib-naïve next-generation percent targeted metastases responses central therapeutics potent therapies group study innovative inhibitors tumors treatment failed
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more